London-listed gene therapy firm Oxford Biomedica has announced the appointment of pharmaceutical executive Colin Bond to its board, as Leone Patterson steps down. Reports Technology News
Bond, set to join the life sciences company in January 2025, began his career as a pharmacist and management consultant, holding roles at Procter & Gamble, Arthur Andersen, and PwC.
In recent years, Bond served as chief financial officer at Zürich-listed pharmaceutical company Sandoz and has held senior executive positions at Vifor Pharma and Evotec.
“Oxford Biomedica’s position as a leader in cell and gene therapy manufacturing, combined with its innovative approach and strong client partnerships, presents a compelling opportunity that I have recently watched with interest,” said Bond.
I am excited to join the board at this important time and look forward to working with the team to support Oxford Biomedica’s continued growth and success in enabling the delivery of life-changing therapies to patients worldwide.”
